This is a comparative prospective study conducted for a period of 2 years from December 2012 to December 2014 in the Postgraduate Department of Otorhinolaryngology, Head and Neck Surgery, Government Medical College, Srinagar, in collaboration with the Department of Biochemistry. A total of 118 subjects were enrolled in the study design, which included 98 histopathologically confirmed head and neck malignant cases and 20 healthy controls. The aim of the study was to compare the ELISA with polymerase chain reaction (PCR) for detection of Epstein-Barr virus (EBV) in head and neck carcinoma cases and compare such results with controls. Results: Around 32.65 and 42.85% of patients were positive for EBV with PCR and ELISA, respectively. When these results were compared with controls, it showed statistically significant results; only 5% of subjects in controls were positive for EBV (p value = 0.015) with PCR while as many as 15% with ELISA (p value = 0.049). The sensitivity and specificity of ELISA are 100 and 84.85%, respectively, with diagnostic accuracy of the test 89.8% (Cohens κ value = 0.7853).
IntroductIon
Head and neck carcinomas are a heterogeneous group of malignancies and can be classified into different subgroups according to the primary tumor site and the histological type. Squamous cell carcinoma (SCC) is the most common histology in mucosal sites of the upper aerodigestive tract. Nasopharyngeal carcinoma (NPC), with a unique geographical and ethnic distribution and high radio-and chemosensitivity, is usually considered separately from other head and neck carcinomas. The undifferentiated subtype of NPC has a strong association with Epstein-Barr virus (EBV). 1 -3 Head and neck squamous cell carcinoma (HNSCC) is thought to account for an estimated 650,000 new cancer cases and 350,000 cancer deaths worldwide per year. 4 Alcohol consumption and smoking tobacco have been implicated in approximately 75% of HNSCC. 5 , 6 Chewing tobacco or betel quid are known risk factors for HNSCC. 7 EBV is a herpesvirus that has been linked to several human malignancies. 8 It is present in the tumor tissue of nasopharyngeal undifferentiated carcinoma and various lymphoid malignancies. 1 -3 , 8 , 9 The virus is also present in the tumor cells of a number of nonnasopharyngeal head and neck carcinomas (NNHNCs). 10 -19 In particular, it is strongly associated with lymphoepithelial carcinoma (LECA) of the salivary glands in Eskimos and Asian patients. 1 , 16 , 17 , 20 , 21 The antigens of EBV are either the nuclear core early antigen (EA) or the viral capsid antigen (VCA). EBVassociated malignancies are often characterized by markedly high titers against EA and IgG/IgA VCA. The EBV genome is contained in all malignant NPC cells and it encodes viral proteins that contribute to the malignant phenotype. 22 , 23 Epstein-Barr virus positivity (EBVP) in lymphoma is discerned in 70% of mixed cellularity, 95% of lymphocyte-depleted lymphoma cells, and 10-40% of nodular sclerosis; the lymphocyte-predominant Hodgkin's disease subtype is almost always EBV negative. 24 Several types of non-B-cell, non-Hodgkin's lymphoma are associated with EBV. 25 , 26 
MAterIAls A n d Methods
The present study was conducted in the Postgraduate Department of Otorhinolaryngology, Head and Neck Surgery, Government Medical College, Srinagar, in collaboration with the Department of Biochemistry. Presently, comparative noninvasive plasma-/serumbased detection of cell-free EBV DNA by polymerase chain reaction (PCR)-based methods is being done. In this study, we compared ELISA with PCR in detection of EBV from plasma samples of all cases and controls. All patients of histopathologically confirmed malignancies of head and neck were enrolled in the study after a proper written consent. Thyroid cancers, metastatic carcinomas from other sites, and carcinoma with unknown primary were excluded from the study. All enrolled patients were evaluated in 7 detail, and full ENT workup was done. Beside routine investigations, special investigations like CECT, MRI, USG, fiber-optic laryngoscopy, and sinonasal endoscopy were performed as and when required for proper staging and comprehensive management.
A 5-mL venous blood sample was collected from each cases and controls in heparin vials and sent to the Department of Biochemistry where serum was separated using a centrifuge and the remaining blood was stored at −20°C for future use. Freshly separated serum samples were used for detection of the antibody of IgM class against the EBV capsid antigen in all cases and controls using ELISA (DS-EIA-ANTI-EBV-VCA-M kit). DNA was extracted from stored blood samples by using the DNA extraction kit (Zymo Research USA). Extracted DNA was stored at −20°C for future analysis.
Real-time PCR
Polymerase chain reaction amplification was done on a thermal cycler (Eppendorf) using the Norgen PCR kit (Norgen Biotech Corp, Canada). Polymerase chain reaction products after amplification were run on 2% agarose gel to detect amplicons. These amplicons were visualized by the gel documentation system (GENETIX).
results
Out of total 98 patients, 70 were males and 28 females with male/ female ratio of 2.5:1.The lowest age encountered was 2 years while the oldest being of 75 years with the mean age of 48.54 and median of 57.5 years. A total of 7 (14.28%) patients were from urban areas while 42 (85.71%) were from rural areas. A total of 68 (69.38%) patients were active smokers while only 30 (30.61%) were nonsmokers. None of the patients were alcoholic or tobacco chewer. The most common tumor encountered in the study was carcinoma of larynx with 40 cases (40.81%), followed by lymphomas with 20 cases (20.40%), and the least common was carcinoma of external ear, with only 2 cases. Table 1 shows the site distribution of tumors.
It was seen that 42 patients out of 98 were positive for the IgM EBV antibody by ELISA (42.85%). Highest number of patients positive for EBV IgM antibodies with ELISA were of NPC (75%), followed by salivary gland tumors (66.66%) and lymphomas (60%). Same is depicted in Table 2 and Figure 1 .
It was seen that the EBV DNA detected by PCR was present in 32.65% of nonendocrine head and neck malignancies only. Highest percentage of EBV DNA is seen in patients of NPC (75%) followed by lymphomas (40%), as shown in Table 3 .
It was seen that with increase in the tumor "T" and/or the nodal "N" stage of the tumor, the percentage of EBVP increased by the ELISA method. For TI/T2, EBVP was ~20% and increased to 50% when the stage was T3/T4 with the p value of 0.043 (Fischer's exact test), which is statistically significant. While for the N stage, EBVP was 27.77% in N0 and increased to ~50% in the N1/N2 stage, with the p value of 0.198 (Fischer exact test), which is insignificant as shown in Table 4 .
It was seen that with increase in the "T" and /or "N" stage of the tumor, the percentage of EBVP increased by the PCR method also. For T1/T2, the EBVP was 25% and increased to 35% in T3 and 50% in T4, respectively, with p value of 0.504 (Fischer exact test). For N0/ N1, EBVP was ~27% and increased to 38.46 in N2 with the p value of 0. 734 (Fischer exact test), which is statistically insignificant. Table 5 depicts the same. Table 6 and Figure 2 show that the plasma EBV is seen in 42.85% of patients as against only 15% in the control group, with p value of 0.049 (Fischer exact test), which is statistically significant.
From Tables 7, 8 and Figure 3 , it is seen that the plasma EBV detection by PCR in patients is 32.65% as compared to only 5% in controls with p value of 0.015 (Fischer exact test), which is statically significant.
dIscussIon
In the study, males were more commonly affected than females. Out of 98 patients in our study, 70 were males and 28 were females with the M/F ratio of 2.5:1. We believe that male predilection is because of them being addicted to smoking, alcoholism, and tobacco chewing and being fortunate enough to be brought to tertiary center for treatment. Many other studies have found this male predilection in head and neck malignancies like the study by Yu et al., 27 Atlana et al., 28 and Abdulamir et al. 29 We found that most of our patients (70%) presented to us in the fourth decade of life. A study by Kamel et al. 30 has also found maximum number of HN malignancy in this decade, while the National Cancer Institute 31 observed that head and neck cancers are diagnosed more often among people over age 50 than they are among young people. Early presentation of patients in our study may be because of the fact that in Kashmir heavy smoking by young population is on rise due to heavy psychological trauma and may be also because of easy access to the tertiary care hospital (GMC, Srinagar).
The present study has 70% of patients who were smokers while only 30% were nonsmokers, which is consistent with the study of Wyss et al., 32 who in his study found that cigarette smokers had elevated odds ratios for head and neck cancers, and extensive literature about the smoking and head and neck carcinomas confirmed our observations.
The most common carcinoma in our study was carcinoma of larynx followed by lymphomas; carcinoma of larynx was found in 40 (40/98) patients ( 40.81%), which was similar to the study of Majid et al. 33 who in his study found that 20 out of 41 head and neck carcinomas were laryngeal carcinomas (48.78%). Similar findings were seen in the study of Yu et al., 27 who in his study "Plasma Similar observations were confirmed by Yu et al. 27 who found that plasma EBV DNA is detectable in 20.0% of the patients.
Oral cavity was seen to be involved in only 10 (10.20%) of our cases. The reason for this low percentage is that gutka and tobacco chewing is not common in Kashmiri population. None of the patients were positive for EBV with either ELISA or PCR. This is in disagreement with Mao and Smith 35 and Horiuchi et al. 36 who showed that 35% and 33.3% of their examined SCC of oral cavity cases, respectively, were infected with EBV. They stated that the positive rate was higher in malignant lesions than in benign ones and agreed that EBV had a role in carcinogenesis. The similar disagreement with our study was also seen in the study of Sand et al. 37 on the "prevalence of Epstein-Barr virus in oral squamous cell carcinoma (OSCC), oral lichen planus (OLP), and normal oral mucosa (NOM)." They examined 29 patients of OSCC, 23 OLP, and 67 NOM cases for EBV DNA analysis. They found that prevalence of EBV in patients with oral mucosal disease is 32.1%. Of the OSCC patients 37.9% and of the OLP 26.1% were positive for EBV.
The current study found only eight (8.16%) cases of NPCs and this low percentage seen in our study is well documented in the literature. In spite of being less in number, NPC was the most common tumor associated with EBV, with six out of eight (75%) cases being positive for the virus. The results were same with both ELISA (EBV anti-IgM VCA) and PCR. Similar findings of high viral In the present study, hypopharyngeal cancer was seen in only four (4.08%) patients and none was positive for EBV with either the ELISA or PCR method. In contrast, study by Yu et al. 27 shows EBV detection rate to be 43.8% in 16 patients of hypopharynx cancer.
The current study had 20 (20.40%) cases of lymphomas, which included 6 Hodgkin's and 16 non-Hodgkin's lymphomas with the EBVP of 40% with PCR. Reports less than our observations were seen by Trimeche et al. 40 who in his study found that 28 out of 126 cases (22.2%) of lymphomas were positive for EBV by in situ hybridization.
In the present study, ELISA was found positive for IgM anti-VCA (EBV) in 42.85% (42/98) of patients in contrast to only 15% (3/20) of controls, which is statistically significant (p = 0.049), while in HNSCC it was found in 30.55 % patients only (22/72), which is in contrast with the results of Morshed et al. 41 who in his study indicated that only 5 (12.8%) of 38 patients with HNSCC were positive for anti-VCA (IgM) and all the controls showed negative results. Similar contrast results were also noted by Kim et al. 42 who in his study found 9 (12%) of the total 72 patients of HNC showed EBVP of tumor, which depends mainly on pathology and sites but not on tumor staging, age, sex, or smoking status. While a study by Majid et al. 33 found that the serum antibody levels against VCA (IgA) and EA (IgA) were significantly elevated in patients with SCC when compared to controls, which is consistent with our results.
The current study showed that 32.65% (22/98) of patients and 5% (1/20) of controls had EBVP when PCR was employed as the detection method, with the p value of 0.035, which is statistically significant (Fischer exact test). Similar reports were confirmed by Yu et al. 27 who in his study observed that 30 patients (29.7%) and 2 controls (4.2%) had detectable plasma EBV DNA. The difference in proportion was statistically significant (p = 0.0004). Plasma EBV DNA was detected in all of the patients with Epstein-Barr virus encoded RNA-positive tumors and in 23 of 94 (24.5%) patients with tumors of EBER-negative or unknown status. The proportion of plasma EBV DNA-positive cases in either group was significantly higher than that in the controls (p = 0.0027), which is in accordance with our results. The difference with our study is that Yu et al. 27 excluded NPC while we had four cases of NPCs.
Another similar study by Goldenberg et al. examined 300 head and neck cancer samples excluding NPC for the presence of EBV using quantitative PCR. He observed that 3 of 300 (1%) tumor samples were overtly positive for EBV DNA. A total of 5 of 300 (2%) tumor samples showed low levels and 68 of 300 tumor samples (23%) showed trace levels of EBV DNA. Thus, the total 25.33% of patients were positive for EBV, which is correlating our observations.
The present study confirmed that with increase in the T/N stage of the HNSCC and LEC, the EBVP increased. When ELISA was employed for detection of EBV, the EBVP increased from ~20% to 50% with the increase in stage from TI/T2 to T3/T4, respectively, with p value of 0.043 (Fischer exact test), which is statistically significant. While in the N stage it was seen that EBVP increased from 27.77% to ~50% in N0 and N1/N2 stages, respectively, with p value of 0.198 (Fischer exact test), which is statistically insignificant. Insignificant findings were also seen with EBV PCR and the stage of tumor. For T1/ T2, the EBVP is 25% and increases to 35% and 50% with increase in the stage from T3 to T4, respectively, with p value of 0.504 (Fischer exact test). For N0/N1, EBVP is ~27% and increases to 38.46% in N2 with p value of 0.734 (Fischer exact test).
Kamel et al. 30 in his study of EBV in HNSCC found no significant increase in EBV antibody titer with stage of tumor, which is 27 states in his study that EBV DNA concentrations in patients with SCC of different stages and T stages did not vary significantly with these parameters, thus simulates our observations. The current study confirmed that ELISA is more sensitive but less specific than PCR in detecting plasma EBV with sensitivity and specificity of 100% and 84.5%, respectively. These observations are in accordance of with the study of Kamel et al. 30 who in his study compared immunohistochemical staining and plasma ELISA for EBV detection in head and neck carcinomas and found that 19 (38%) patients were immunoreactive using the immunohistochemical staining method and 41 (82%) were positive using ELISA. Anti-EBV staining in the control sections revealed negative results. Whereas four (93.3%) of controls were positive with ELISA. They concluded that ELISA gave more false positive results.
conclusIon
• Epstein-Barr virus is a potential carcinogenic virus which, has definite association with head and neck malignancies even in endemic areas. • Most of the head and neck malignancies are present in advanced stages, so there is a need to screen the population early to prevent dreadful morbidity and mortality associated with disease. • Noninvasive simple plasma-based detection of EBV may serve as a potential screening test. • Antibodies against the certain antigens of the EBV can be detected in large percentage of general population. The detection of these antibodies indicates antigenic stimulation with the virus, although their presence in suspected cases cannot be used definitively for the diagnosis of occult head and neck carcinomas. • Recent data indicate the role of EBV in the epigenetic alterations in several types of cancers including gastric carcinoma, NPC, and lymphomas. • A consistent association between EBV and LECA of the salivary gland was found. • The presence of EBV in these tumors represents a potential "tumor-specific" targeting opportunity for the development of new therapeutics.
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